A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 274
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : tPSA
Long Form : total PSA
No. Year Title Co-occurring Abbreviation
2022 Clinical Application of Prostatic Exosomal Protein and Prostate-Specific Antigen Levels in the Detection of Prostate-Related Diseases. AP, CP, fPSA, PCa, PSA, PSEP
2022 Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions. AUC, CI, csPCa, fPSA, PCa, PHI, PI-RADSv2, PSA, PSAD, ROC, TRUS
2022 Correlation between prostate volume and prostate-specific antigen in Nigerian men with symptomatic histologically-diagnosed benign prostatic hyperplasia. BPH, fPSA, PSA, PV, TRUS
2022 Effects of cycling and rowing on serum concentrations of prostate-specific antigen: A randomized study of 101 male subjects. fPSA, PSA
2022 Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5-9.9 ng ml-1. AUC, fPSA, PV, ROC
2022 Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer. AUC, fPSA, MPV, PCa, PDW, PSA, ROC
2021 A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting. AUC, mpMRI, PCa, PSA, PSAD
2021 Can serum endoglin be used to improve the diagnostic performance in prostate cancer? NPV, PCa, PSA
2021 Characteristics of alpha2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level. MRI, PC, PI-RADS, PSA, PSAD, S23PSAD
10  2021 Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0-25.0 ng ml-1 in Western China. AUC, BPD, fPSA, PCa, TNM
11  2021 Detection of N,N-diacetyllactosamine (LacdiNAc) containing free prostate-specific antigen for early stage prostate cancer diagnostics and for identification of castration-resistant prostate cancer patients. BPH, CRPCa, fPSA, HG PIN, mpMRI, PCa
12  2021 Developing Strategy to Predict the Results of Prostate Multiparametric Magnetic Resonance Imaging and Reduce Unnecessary Multiparametric Magnetic Resonance Imaging Scan. DCA, fPSA, mpMRI, PCa, PSA, PSAD, PV
13  2021 Is serum PSA a predictor of male hypogonadism? Testing the hypothesis. AUC, fPSA, MH, MH, OR, PSA, ROC
14  2021 PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite Prognosis in Prostate Cancers. AR, CRPC, fPSA, mPR, NEPC, PAQR, PgR, PGRMC1
15  2021 Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection. AUC, csPCa, DCA, PCa, PHI, PHID, PSA, PSAD
16  2021 Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer. AUC, BPH, ELISA, IgG-Lys, Lys, PC, PLG, PLG, ROC, Sn, Sp
17  2021 Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression. fPSA, PSA
18  2021 The Impact of Cell-free Plasma DNA on Metastatic and Nonmetastatic Prostate Cancer. BPH, cfDNA, GI, GII, GIII, GIV, PC
19  2021 The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical Bacillus Calmette-Guerin vaccine therapy in patients with nonmuscle invasive bladder cancer. ADC, BCG, DRE, DWI, GP, mpMRI, NMIBC, PSA, SI, T1WI, TURBT
20  2020 Assessment of expression levels of leptin and leptin receptor as potential biomarkers for risk of prostate cancer development and aggressiveness. PCa
21  2020 Association of Gleason score with PSA Values and Serum Testosterone Levels Measured Prior To Prostate Biopsy. DRE, fPSA, PCa, PSA, PSAD, PV
22  2020 Cost-Effectiveness Analysis of Prostate Health Index in Decision Making for Initial Prostate Biopsy. PHI, PSA
23  2020 Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection. fPSA, HGPIN, p2PSA, PCa, PHI, PHID
24  2020 Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy. PSA
25  2020 [PSA derivative indicators in the diagnosis of prostate cancer: Advances in studies]. ---
26  2020 [Stored autologous blood transfusion does not increase recurrence of prostate cancer after radical prostatectomy: A preliminary study]. DRE, fPSA, SABT
27  2019 Clinical significance of the LacdiNAc-glycosylated prostate-specific antigen assay for prostate cancer detection. AUC, csPC, LDN-PSA, LDN-PSAD
28  2019 Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free Prostate-Specific Antigen. AUC, CN, fPSA, I-MC, I-MC, iPSA, nPSA, PSA, WT
29  2019 Determination of Free-PSA (fPSA) and fPSA/PSA-Ratio Using A Point-of-Care Device. fPSA, PC, POC, PSA
30  2019 Development and Evaluation of an Immunoglobulin Y-Based ELISA for Measuring Prostate Specific Antigen in Human Serum. IgY, LoB, LOD, LOQ, PSA
31  2019 Development and internal validation of a novel PHI-nomogram to identify aggressive prostate cancer. AUC, PCa, PHI
32  2019 Development and validation of a preoperative nomogram for predicting positive surgical margins after laparoscopic radical prostatectomy. C-index, CI, fPSA, LRP
33  2019 Establishment of reference intervals for serum [-2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men. fPSA, p2PSA, PCa, PHI, RIs
35  2019 Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan. AUCs, fPSA, p2PSA, PCa, PHI, PSA
36  2019 The Effect of Intravesical Prostatic Protrusion in Patients with Benign Prostatic Hyperplasia: Controlled, Clinical Study. fPSA, IPP, IPSS, PSA, PV, PVR
37  2018 Discordant prostate specific antigen test results despite WHO assay standardization. fPSA
38  2018 Preanalytical stability of [-2]proPSA in whole blood stored at room temperature before separation of serum and plasma: implications to Phi determination. fPSA, Phi, PSA
39  2018 Prospective performance of the Prostate Health Index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4-10ng/mL and negative digital rectal examination. DRE, PHI, PSA
40  2018 Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function. F/T, KLK3, PCa, PSA, SNPs
41  2018 Simultaneous immunoassays of dual prostate cancer markers using a SERS-based microdroplet channel. fPSA, SERS
42  2018 The application of p2PSA% and prostate health index in prostate cancer detection: Aprospective cohort in a Tertiary Medical Center. AUC, fPSA, PHI, PSA
43  2017 Different free prostate-specific antigen to total prostate-specific antigen ratios using three detecting systems. BPH, fPSA, PCa, PSA
44  2017 Dual-labeled chemiluminescence enzyme immunoassay for simultaneous measurement of total prostate specific antigen (TPSA) and free prostate specific antigen (FPSA). ALP, AMPPD, CLEIA, fPSA, fPSA, HRP, PSA
45  2017 Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China. AUC, PCa, PHI, PSA
46  2017 Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. ---
47  2017 Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour. BBD, BC, FBG, FBS, fPSA, LDL, OCP, PSA
48  2017 Tumor marker alpha-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer. fPSA, PCa, PSA, TRUS
49  2017 Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience. AUC, fPSA, p2PSA, PHI, PSA
50  2017 [Value of PI-RADS v2 scores combined with prostate specific antigen in diagnosis of peripheral zone prostate cancer: a logistic regression analysis]. PCa, PI-RADSv2, PSA, PSAD, PZ, ROC
51  2016 A portable chemiluminescence imaging immunoassay for simultaneous detection of different isoforms of prostate specific antigen in serum. CCD, CL, fPSA, MORP, NC, PSA, SBP
52  2016 Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia. fPSA, PV
53  2016 Classifying prostate cancer patients based on total prostate-specific antigen and free prostate-specific antigen features by support vector machine. fPSA, PCa, PSA, SVM
54  2016 Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study. fPSA, PCa, PHI, PSAD
55  2016 Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL. AUC, fPSA, miRNA, PCa, PSA, qRT-PCR, ROC
56  2016 Effect of body mass index on the performance characteristics of PSA-related markers to detect prostate cancer. AUC, BMI, PCa, PHI, PSA
57  2016 Evaluating serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 as markers in prostate cancer diagnosis. AUC, BPH, fPSA, IGF1, IGFBP3, PCa, PSA
58  2016 Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination. AUC, DCA, DRE, PHI, PSA, TRUS
59  2016 Influence of age on seven putative prostate tumor markers: a cohort study in Chinese men. fPSA, p2PSA, PHI, PSA
60  2016 Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all? fPSA, PCa, PSA, SHBG
61  2015 Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. AUC, fPSA, PCa, PHI, PSA
62  2015 Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review. fPSA, PCa, PHI, TP
63  2015 Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL. LUTS, PCa, PSA
64  2015 Evaluation of free-to-total prostate specific antigen (F/T PSA), prostate specific antigen density (PSAD) and (F/T)/PSAD sensitivity on reduction of unnecessary prostate biopsies for patients with PSA in gray zone. BPH, fPSA, PSA, PSAD
65  2015 Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer. FRAP, IMA
66  2015 PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. GS, PCa, PCA3, PSA
67  2015 Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values. DRE, PCa, PSA, ROC, TRUS
68  2015 Perineural invasion in prostate biopsy specimens is associated with increased bone metastasis in prostate cancer. GS, PCa, PNI, WBBS
69  2015 Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects. fPSA, MRI, PHI, pPSA, PSA, PSAD, PSADT, PSAV
70  2015 Stability and accuracy of total and free PSA values in samples stored at room temperature. fPSA
71  2015 The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years. ANN, AUC, DCA, fPSA, PHI, PRIAS, PSA, WHO
72  2015 Total, free, and complexed prostate-specific antigen levels among US men, 2007-2010. BMI, cPSA, fPSA, PSA
73  2015 [Pro-prostate-specific antigen and its related indexes in the diagnosis of prostate cancer]. fPSA, PHI, proPSA
74  2014 Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study. BMI, fPSA, p2PSA, PHI, PSA
75  2014 Comparison between clinical significance of serum proinflammatory protein interleukin-6 and classic tumor markers total PSA, free PSA and free/total PSA prior to prostate biopsy. BPH, fPSA, GS, IL-6, PCa, PIN
76  2014 Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer. fPSA, PC, PSA
77  2014 Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. AUC, AUC, p2PSAD, PCa, PHI, PHID, PSAD
78  2014 Low free to total PSA ratio is not a good discriminator of chronic prostatitis and prostate cancer: An Indian experience. fPSA
79  2014 Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less. PSA
80  2014 Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDA. fPSA, PCa, PSA, SHBG
81  2014 Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. fPSA, GS, PCa, PHI, PSA, RP
82  2014 Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy. AUC, fPSA, Gls, p2PSA, PCa, PSA
83  2014 Prostate cancer biomarkers: an update. fPSA, PCA, PSA
84  2014 Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. AUCs, CI, PCa, PHI, PSA
85  2014 Prostatic and testicular parameters in lepromatous patients. fPSA, LL, PSA, PSAD
86  2014 Stability of [-2]Pro-PSA in whole blood and serum: analysis for optimal measurement conditions. PHI, RT
87  2014 The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs). AUC, LRs, PCOS, PCOs, PSA, ROC
88  2014 The influence of prostate volume on cancer detection in the Chinese population. DRE, PCa, PSA, PV, TRUS
89  2014 Value of prostate gland volume measurement by transrectal US in prediction of the severity of lower urinary tract symptoms. fPSA, IPSS, LUTS, TRUS
90  2014 [The practical application of marker -2proPSA and health index of prostate phi in diagnostics of prostate cancer]. PSA
91  2013 A new model consists of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of prostate cancer. fPSA, IPP, IRPPS, PCa, PSA, PSAD, ROC, TPV, TRUS, TZV
92  2013 Age-specific prostate specific antigen cutoffs for guiding biopsy decision in Chinese population. DRE, fPSA, PCa, PSA, ROCs
93  2013 Association of a common variant at 10q26 and benign prostatic hyperplasia aggressiveness in han chinese descent. BPH, fPSA, IPSS, PCa, TPV
94  2013 Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0ng/ml at population screening. PSA
95  2013 Differences in prostate cancer detection rates according to the level of glomerular filtration rate in patients with prostate specific antigen levels of 4.0-10.0 ng/ml. fPSA, GFR, PSA
96  2013 Do the values of prostate specific antigen obtained from fresh and dried urine reflect the serum measurements? fPSA
97  2013 Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA. SNPs
98  2013 Opium consumption is negatively associated with serum prostate-specific antigen (PSA), free PSA, and percentage of free PSA levels. fPSA, PSA
99  2013 Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination. DRE
100  2013 Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study. CI, PSA, PSADT, ROC, vPSA